Laboratoires Pierre Fabre and XtalPi announced on November 9, 2026 an agreement to discover novel small-molecule clinical candidates across multiple research programs. XtalPi will contribute integrated AI capabilities and a robotics platform, while Pierre Fabre will select and advance compounds in oncology, potentially dermatology, and rare diseases.
The partners are directing that work toward challenging and historically hard-to-drug targets, which they associate with significant unmet medical need and substantial opportunities for innovative drug discovery.
That focus gives context to the companies’ stated goal of accelerating the identification of high-quality clinical candidates. The emphasis on both quality and speed means the intended output is compounds strong enough to become clinical candidates in areas where discovery has been difficult.
Design and Development Responsibilities
XtalPi will handle de novo design, meaning the creation of new molecular structures, and deliver novel small-molecule therapeutics against undisclosed targets. This places its integrated AI capabilities and robotics platform at the front end of the partnered discovery process, with the resulting molecules moving into Pierre Fabre’s selection work.
Pierre Fabre will apply expertise in disease biology, discovery, translational research, and clinical development to select and advance the most promising compounds. It will also be responsible for subsequent clinical and commercial development. The agreement thus gives Pierre Fabre continuity across the selection decision and the later development path, while XtalPi’s defined responsibility remains the design and delivery of the underlying molecules.
The acceleration goal expressly spans multiple programs in oncology and potentially other therapeutic areas. That scope gives XtalPi’s platform several research settings in which its designs can be assessed using Pierre Fabre’s disease-biology and translational expertise.
Payments and R&D Strategy
The agreement includes an upfront payment, multiple milestone payments, and downstream economic participation.
For Laboratoires Pierre Fabre, the agreement is a strategic addition to its R&D roadmap and strengthens its drug-discovery capabilities. Francesco Hofmann, head of pharma research and development at Laboratoires Pierre Fabre, described XtalPi’s AI expertise as “a critical addition to our R&D Data and AI roadmap and to our discovery engine.”
For XtalPi, the collaboration advances its effort to apply AI and robotics to de novo drug discovery. The two stated rationales are complementary: Pierre Fabre is adding an AI-enabled discovery component to its research roadmap, while XtalPi is applying its platform within partnered therapeutic programs that have a defined route into clinical and commercial development.
The consequential test sits at the handoff between molecular design and development. For targets that have historically resisted drug discovery, the partnership’s value depends on whether XtalPi’s designed molecules become compounds Pierre Fabre considers promising enough to advance, and ultimately whether they meet the companies’ goal of high-quality clinical candidates in areas of unmet medical need.
